FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Ouimette Mike (Last) (First) (Middle) C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE																tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title Other (specify below) General Counsel & Corp. Sec'y				vner specify
(Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)						If Amendment, Date of Original Filed (Month/Day/Year)									. Indivine)					
		Tab	le I - No	on-Deri	vativ	e Se	curi	ties A	\cqu	iired,	Dis	sposed o	f, or Be	neficia	ally	Owned				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						r) E	2A. Deemed Execution Date, if any (Month/Day/Year)		, ⊺ı C	3. Transaction Code (Instr. 8)			es Acquired Of (D) (Instr	i (A) or : 3, 4 and	and 5) Secur Benef Owne		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									С	ode	٧	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(111311. 4)
Common Stock				01/23/2023		T				M		10,000	A	\$11.	.86 1		5,947		D	
Common Stock					01/23/2023					М		10,000	A	\$24.	32	25,947			D	
Common Stock 0					01/23/2023				5	S ⁽¹⁾		20,000	D	\$34.1	939	5,947			D	
		-	Table II									osed of, convertil				wned				
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Exec tv or Exercise (Month/Dav/Year) if an		3A. Deen Executio if any (Month/D	on Date, Transact		Instr.	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title an of Securit Underlyin Derivative (Instr. 3 a	ties ng e Securit	D S (III	Price of erivative ecurity nstr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)

Explanation of Responses:

\$11.86

\$24.32

Stock Option (right to buy)

Stock Option

(right to

buy)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.

M

M

(A) (D)

10,000

10,000

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date.

(2)

(3)

3. 25% of the shares subject to such option vested on October 1, 2021 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

/s/ Mike Ouimette

01/25/2023

77,000

98,240

D

D

** Signature of Reporting Person

10,000

10,000

\$<mark>0</mark>

\$<mark>0</mark>

01/25/2032

10/08/2030

Common Stock

Common

Stock

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

01/23/2023

01/23/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.